Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Diabetic foot ulcers, a complication of diabetes leading to 80.000 lower limb amputations
annually in the US, are a significant burden to our health system, costing more than a
billion dollars annually. Here, we propose a novel combination of two drugs (Mozobil® and
Regranex®Gel) to mobilize a specific sub-type of stem cells (endothelial progenitor cells)
from the bone marrow and traffic them toward the wound, increasing the blood supply that
subsequently improves wound healing. Because we are using the human body's own resources to
regenerate itself by targeting and correcting the underlying pathophysiology, we believe that
this novel therapy yields great promise in the treatment of diabetic foot ulcers.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Genzyme, a Sanofi Company National Institutes of Health (NIH)
Treatments:
Becaplermin JM 3100 Platelet-derived growth factor BB Plerixafor